Presentation

Company Profile
Alligator Bioscience is an immune-oncology company developing antibodies aimed at a range of cancer targets. It specializes in the development of tumour-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The firm currently has four active clinical programs.

Recent highlights
In March 2021 the company appointed Søren Bregenholt as new CEO. In May, preclinical data on the lead asset mitazalimab was published in the scientific journal Cancer Immunology, Immunotherapy. The data showed that mitazalimab activated antigen-presenting cells and improved the expansion of tumour-reactive T cells, while enhancing the anti-tumour efficacy of a model cancer vaccine in vivo. In June, Alligator presented interim data from the Phase I, open-label, dose-escalating trial of ATOR-1017. The data suggest that the drug has a favourable safety profile, and indicate that the mechanism is relevant, demonstrated by the increase of anti-tumour immune cells. The study is still ongoing with the MTD not yet reached. In August, Alligator announced that it entered a research collaboration and license agreement with Orion Corporation

Outlook
The company is ready to initiate the OPTIMIZE-1 trial, an open label multi-centre study assessing the efficacy of mitazalimab. First interim readout is expected for H2 2021, and interim efficacy results are projected for H2 2022. Simultaneously, the company’s objective is to submit the CTA for a Phase II efficacy study on ATOR-1017 by end of 2021.